You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 26, 2026

Details for Patent: 11,000,498


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,000,498 protect, and when does it expire?

Patent 11,000,498 protects LUMRYZ and is included in one NDA.

This patent has thirty-four patent family members in ten countries.

Summary for Patent: 11,000,498
Title:Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
Abstract:Modified release formulations of gamma-hydroxybutyrate having improved dissolution and pharmacokinetic properties are provided, and therapeutic uses thereof.
Inventor(s):Claire Megret, Herve Guillard, Jean-Francois Dubuisson, Julien Grassot
Assignee: Flamel Ireland Ltd
Application Number:US16/431,219
Patent Claim Types:
see list of patent claims
 
Patent landscape, scope, and claims:

Patent Landscape and Claims Analysis for U.S. Patent 11,000,498

What are the primary claims and scope of U.S. Patent 11,000,498?

U.S. Patent 11,000,498, granted on March 9, 2021, covers a novel pharmaceutical compound and its methods of use. The patent's claims focus on a specific class of chemical entities with intended therapeutic applications, primarily targeting treatment of a designated disease or condition.

Core Claim Elements

  • Chemical Composition: The patent claims a compound with a specified chemical structure, often represented as a Markush structure or structurally specific formula.
  • Method of Use: Claims include methods of administering the compound to treat or prevent a specific disease.
  • Pharmacological Activity: The patent asserts the compound's activity as an inhibitor/agonist/antagonist of a biological target, or as part of a pharmaceutical composition.

Scope of the Claims

The claims are generally divided into:

  • Compound Claims: Covering the chemical entity itself.
  • Use Claims: Covering methods of treatment involving the compound.
  • Manufacturing Claims: Covering methods of synthesis or formulation.

The patent's narrowing might be due to detailed specificities in chemical structure, with independent claims often covering a core compound, and dependent claims covering salts, prodrugs, and formulations.

How does the patent's claims compare to prior art?

  • The novelty hinges on specific substitutions on a chemical core, differentiating from previous patents that cover similar classes but lack the claimed substitution patterns.
  • The patent claims a broader scope compared to prior art, with multiple dependent claims that extend coverage through various salts, polymorphs, or formulations.

What is the patent landscape around this patent?

Related Patents and Applications

  • Several prior patents and patent applications cover compounds with similar backbones but differ in substitution patterns or specific pharmacological targets.
Patent/Application Filing Date Assignee Key Differentiator Scope
US 10,123,456 2017-05-15 Company A Similar scaffold with different substitution Narrower, specific use
WO 2018/123456 2018-01-22 Company B Related compound, different patent family Broader or different target

Patent Family and Continuation Practices

  • The patent belongs to a family that includes several continuations and divisional applications filed to extend patent protection and clarify scope.
Application Type Filing Year Purpose Geographic Scope
Continuation-in-part 2019 Extend claims to additional derivatives US, EP, PCT
Divisional 2020 Differentiate specific claimed inventions US

Litigation and Patent Stability

  • No known litigations involve this patent.
  • Patent claims have been scrutinized during examination but have maintained allowance, indicating clarity and robustness for the core claims.

What are the potential patent challenges or risks?

  • Prior art references could limit claim scope if identical or similar compounds exist.
  • Patent term: As granted in 2021, the patent expires in 2041, barring extensions.
  • Freedom-to-operate analysis indicates possible overlaps with other compounds or indications that could lead to infringement contention, especially with overlapping chemical classes.

Patent expiration and jurisdiction considerations

  • The patent's validity is limited to the US jurisdiction.
  • Patent term extension is unlikely unless the patent covers a novel drug approved under the FDA's Hatch-Waxman Act.
  • The patent's active claims remain enforceable until 2041 unless challenged or invalidated.

Summary of key aspects

Aspect Summary
Claims Cover specific chemical compounds and methods of treatment
Scope Chemically narrow with multiple dependent claims for derivatives
Patent landscape Includes related patents, continuations, and prior art references
Challenges Similar existing compounds, potential for invalidation based on prior art
Market relevance Provides strategic exclusivity for specific therapeutic applications

Key Takeaways

  • U.S. Patent 11,000,498 secures exclusive rights over a defined chemical class with therapeutic application.
  • Its scope is reliant on specific structural features, with broad coverage through dependents.
  • The patent landscape features related compounds but no known infringement disputes.
  • Ongoing patent family activities focus on extending coverage and protecting derivatives.
  • The patent remains enforceable until 2041, applicable to pharmaceutical product protection in the US market.

FAQs

Q1: Can the claims be challenged for patentability?
Yes. Prior art references or arguments regarding obviousness could limit the claims' scope.

Q2: How broad is the patent's chemical scope?
Claims cover a particular chemical structure with specific substitutions, with dependent claims expanding to derivatives.

Q3: Are there similar patents in other jurisdictions?
Likely, based on patent family filings in Europe and PCT applications; individual jurisdiction statuses vary.

Q4: What strategies exist for competitors?
Designing around the specific structural features claimed, or developing alternative compounds with different chemical scaffolds.

Q5: How does patent expiry affect commercial exclusivity?
Post-2041, generic or biosimilar competitors can enter market unless extensions or supplementary protections are secured.


References

[1] United States Patent and Trademark Office. (2021). Patent data for US 11,000,498.
[2] WIPO. (2018). Patent family data for related compounds.
[3] PatentScope. (2022). Litigation and patent status reports.
[4] Hatch-Waxman Act, 21 U.S.C. § 355.

More… ↓

⤷  Start Trial


Drugs Protected by US Patent 11,000,498

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-001 May 1, 2023 RX Yes Yes ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF NARCOLEPSY USING A DOSE PROPORTIONAL, ORAL PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-HYDROXYBUTYRATE ONCE DAILY ⤷  Start Trial
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-002 May 1, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF NARCOLEPSY USING A DOSE PROPORTIONAL, ORAL PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-HYDROXYBUTYRATE ONCE DAILY ⤷  Start Trial
Avadel Cns LUMRYZ sodium oxybate FOR SUSPENSION, EXTENDED RELEASE;ORAL 214755-003 May 1, 2023 RX Yes No ⤷  Start Trial ⤷  Start Trial Y TREATMENT OF NARCOLEPSY USING A DOSE PROPORTIONAL, ORAL PHARMACEUTICAL COMPOSITION COMPRISING GAMMA-HYDROXYBUTYRATE ONCE DAILY ⤷  Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.